Clinical Trial Update: GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetics study of GW117 orally disintegrating tablets conducted in healthy subjects; Major depressive disorder is listed as the condi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• GW117 ODT

Snippet

Sponsor: Beijing Greatway Pharmaceutical Technology Co.,Ltd. | Conditions: Major Depressive Disorder | Phase 1 | Status: COMPLETED